Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067) Meeting Abstract
| Authors: | Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; Ferrucci, P. F.; Smylie, M.; Hill, A. G.; Hogg, D.; Marquez-Rodas, I.; Jiang, J.; Rizzo, J.; Larkin, J.; Wolchok, J. |
| Abstract Title: | Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy424.054 |
| Language: | English |
| ACCESSION: | WOS:000459277304403 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy424.054 |
| Notes: | Meeting Abstract: LBA44 -- Appears on page viii735 of the abstract book -- Source: Wos |
